IMPORTANCE Chimeric and murine anti-G D2 antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-G D2 antibody, was constructed.
were enrolled from December 24, 2012, through May 3, 2016 , and all had chemotherapy-resistant stage 4 high-risk neuroblastoma, as evidenced by results of a radiologic study, a bone marrow histologic study, and/or at least 1 prior relapse.
Protocol Treatment
Each cycle comprised (1) subcutaneously administered priming dosage of GM-CSF at 250 μg/m 2 /d on days −4 to 0 (Wednesday through Sunday), followed by a step-up to 500 μg/m 2 /d on days 1 to 5 (Monday through Friday) and (2) hu3F8 infused intravenously for 30 minutes on days 1, 3, and 5 (Monday, Wednesday, and Friday, ie, only 3 doses/cycle). The cytokine GM-CSF was not administered if the absolute neutrophil count was greater than 20 000/μL. Premedication included opiates and antihistamines.
Treatment was repeated 4 times monthly but was deferred if HAHA developed. Patients who completed 4 cycles without the development of progressive disease had the option to continue treatment at intervals of up to 8 weeks between cycles. After cycle 2, patients had the option with each cycle to increase the hu3F8 dose to the highest level at which patients had completed assessment for dose-limiting toxicity (DLT).
Study Design
The 3 + 3 dose-escalation design for phase 1 trials was used. 12 Thus, 3 to 6 patients were treated at each dose level, and the maximum-tolerated dose was the highest level at which 0 of 3 or 1 of 6 patients experienced DLT. Dose level 1 of hu3F8 was 0.9 mg/kg/cycle, which is approximately 27 mg/m 2 /cycle using the standard equivalency calculation (× 30) for converting dose by weight to body surface area. Dose-limiting toxicity was defined as grade 3 toxicity or higher (Common Terminology Criteria for Adverse Events, version 4.0) occurring in cycle 1, days 0 to 21. All patients who received 1 dose of hu3F8 were evaluable for toxic effects. Dose-limiting toxicity included hypertension requiring medication for more than 24 hours; grade 3 or higher capillaryleak syndrome; and pain necessitating 7 doses or more of opioids within 2 hours, with 1 dose defined as 0.1 mg/kg of morphine sulfate. This DLT designation for pain was based on historical experience: wherein an unselected cohort of 50 patients who, in earlier studies, had received 435 administrations of m3F8 and GM-CSF, the proportion of patients treated with 7 doses or more of opioids in 24 hours was 0.06. 13 Grade 3 toxic effects were not considered DLT if they resolved in fewer than 24 hours, which included urticaria (improved to grade ≤2), vasovagal reaction, sinus bradycardia or tachycardia, hypotension, fever, and electrolyte disturbances. Grade 3 toxic effects were not considered DLT if they resolved in fewer than 48 hours and included nausea/emesis, diarrhea, and paresthesia. Other grade 3 or 4 toxic effects were not considered DLT if they returned to baseline by day 21 of cycle 1 or were clearly associated with disease activity or cointerventions.
HAHA and Complement Measurements
Human antihuman antibody was quantified by an ELISA assay validated for its sensitivity, specificity, and interference in accordance with Investigational New Drug 12594. Serum samples were first bound to hu3F8-IgG1-F(ab'2) coated on microplates (ThermoFisher Scientific) and then to peroxidase-conjugated goat antihuman Fc-specific antibody. On the basis of a human high-titer serum reference standard, 42 normal controls were measured to establish an upper limit of normal as mean (±3 SDs) to maximize the positive or negative predictive value of the assay, which served as a cut point for HAHA positivity (1300 U/mL; 3.9 ng/mL). Because hu3F8 mediates CDC in vitro, 7 C3 complement and total hemolytic complement activity (CH50) were measured before and 3 hours after the first infusion of hu3F8 in cycle 1.
Pharmacokinetics
Serum samples were collected before and then after the first hu3F8 infusion on day 1 at 5 minutes, 3 hours, 6 hours, 24 hours, 48 hours (before and 5 minutes after the second hu3F8 dose on day 3), 72 hours, 96 hours (before and 5 minutes after the third hu3F8 dose on day 5), 120 hours, 168 hours, 216 hours, and 264 hours. 14 Serum hu3F8 concentration was quantified using a validated ELISA in accordance with Investigational New Drug 12594. In brief, anti-m3F8 idiotype antibody A1G4 15 was used to capture serum hu3F8 (hu-IgG1 antibody) on microplates followed by peroxidase-conjugated mouse antihuman IgG1 Fc-specific antibody. Color reaction using hydrogen peroxide and o-phenylenediamine was measured with an ELISA plate reader at 490 nm. Serum hu3F8 was quantified by referencing to a hu3F8-IgG1 standard curve. Pharmacokinetic analysis was performed by noncompartmental analysis of the serum concentration-time data using the Phoenix WinNonLin software, version 7 (Certara). On the basis of the dosing interval of 48 hours between doses of hu3F8, the key measurements included area under the serum concentration-time curves, measured using the log-linear trapezoidal calculation method for noncompartmental analysis suggested by the software; peak serum concentration (mean of 5 minutes after infusion on days 1, 3, and 5); trough serum concentration (mean of 5 minutes before infusion on days 3 and 5); terminal half-life; clearance and volume of distribution in steady state; and mean residence time, the theoretical mean time the drug remains in the body and calculated as mean residence time = volume of distribution/clearance.
Treatment Response Assessment
Disease status was assessed after cycles 2 and 4 (a standard for high-risk neuroblastoma) and then at least every 3 months by using computed tomography of the primary site, a 123 I-metaiodobenzylguanidine scan, and a bone marrow histologic study (aspirates and biopsy specimen from bilateral posterior iliac crests and aspirates with or without biopsy specimens from bilateral anterior iliac crests). Response was defined according to the International Neuroblastoma Response Criteria, 16 and 123 I-metaiodobenzylguanidine scan findings were quantified by Curie scores 17 : complete remission, no evidence of neuroblastoma; partial response, 50% or greater decrease in neuroblastoma by radiologic study and bone marrow histologic study results showing complete remission or minimal disease (>0 to ≤5% tumor infiltration); minor response, 50% or greater decrease of any lesion with less than 50% decrease in any other lesions; stable disease, less than 50% decrease but 20% or less increase in any existing lesion; or progressive disease, new site of disease or greater than 20% increase in an existing lesion.
Statistical Analysis
Comparison of responses was performed using the χ 2 test for a significance level of 2-sided P = .05. Statistical analysis was performed with SPSS software (IBM).
Results
Of the 57 participants, 34 (60%) were male and 23 (40%) were female (male-to-female ratio of 1.5), with a median (range) age of 6.8 (2.4-31. 3) years at enrollment and a median (range) time of 3.1 (0.6-9.0) years since initial chemotherapy. Table 1 presents patient characteristics, and eTable 1 in Supplement 2 includes clinical features of patients treated at each dose level. All but 3 patients were previously treated with 1 or more anti-G D2 mAbs, received autologous stem cell transplant, and/or underwent 131 I-metaiodobenzylguanidine therapy.
Toxic Effects
All 57 patients were evaluable for toxic effects. No maximumtolerated dose was identified (eTables 1 and 2 in Supplement 2). Acute toxic effects were manageable, allowing outpatient treatment. No delayed or long-term toxic effects occurred.
Patients received a median (range) of 4 (1-15) cycles of hu3F8 and GM-CSF. Eight patients (14%) received 10 cycles or more. Dosage escalation stopped at 9.6 mg/kg/cycle (dose level 15; approximately 288 mg/m 2 /cycle), based on the plateau of the area under the serum concentration-time curves in pharmacokinetic studies. No association between toxic effects and development of HAHA was found. eTable 2 in Supplement 2 lists the toxic effects observed in 5% of patients or more in cycles 1 or 2. The common adverse effects, as expected with anti-G D2 mAbs, occurred on days of hu3F8 administration and included grades 1 to 2 pain, urticaria, and cough. Grade 3 toxic effects in major organs were limited to transient elevations in liver enzymes in cycle 1 in 10% of patients and in single patients in cycles 2, 6, 7, and 9 . Five patients (9%) developed grades 1 to 2 Adie pupil (mydriasis, abnormal accommodation), including 3 patients after cycle 1, 1 patient after cycle 4, and 1 patient after cycle 10. No other neurologic deficits were noted.
Four patients (7%) experienced DLT (eTable 1 in Supplement 2). Grade 4 anaphylactic reactions (acute unresponsiveness and hypotension) accompanied the first infusion of hu3F8 in 1 patient who received 0.8 mg/kg (2.4 mg/kg/cycle, dose level 3; this patient had previously experienced an identical reaction to m3F8) and in 1 patient who received 2.8 mg/kg (8.4 mg/kg/cycle, dose level 13). One patient had acute, transient renal failure after unreported emesis during the weekend after the completion of cycle 1 (7.8 mg/kg/cycle, dose level 12). The fourth patient who experienced DLT had transient grade 3 or 4 hypertension, which developed after the completion of cycle 1 (9 mg/kg/cycle, dose level 14). Beyond the period of monitoring for DLT (ie, cycle 1), 2 patients (4%) experienced grade 4 toxic effects that necessitated their exit from the study: 1 patient, who had uneventfully received 6 cycles, developed an anaphylactic reaction from the first infusion of hu3F8 (1 mg/kg) in cycle 7 (3 mg/kg/cycle, dose level 4); another patient developed grade 4 angioedema (tongue swelling, stridor) after completing cycle 2 (8.4 mg/kg/cycle, dose level 13).
Pharmacokinetics
Fifty-four of 57 patients (95%) had serum samples for pharmacokinetic analyses (2 patients experienced DLT after the initial infusion, and 1 patient had a missing peak serum concentration of the third dose). Dose escalation was associated with increased serum concentration of hu3F8. Analysis of pharmacokinetics in cycle 1 at each of the 15 dose levels (range, 0.9 mg/kg/cycle to 9.6 mg/kg/cycle) revealed a strong linear correlation between dose and peak serum concentration of hu3F8 (ie, at 5 minutes after infusion on days 1, 3, and 5) (R 2 = 0.9629; Figure 2A ).
A linear correlation was also seen between dose and trough serum concentration (before infusion on days 3 and 5) (R 2 = 0.8658; Figure 2B ). Similarly, a statistically significant association was found between hu3F8 dose and area under the serum concentration-time curves (R 2 = 0.9501; Figure 2C ).
Dose escalation did not change the terminal half-life, with a mean (SD) of 4.08 (1.12) days (eFigure, A in Supplement 2), or the mean residence time (calculated as mean residence time = volume of distribution/clearance; eFigure, B in Supplement 2). This lack of association between dose and elimination of hu3F8 from the body can be attributed to the correlation between volume of distribution and clearance (eFigure, C in Supplement 2).
HAHA Response
Human antihuman antibody was measured after every cycle. Human antihuman antibody positivity developed in 5 of 57 patients (9%) after cycle 1, including in 1 of 10 (10%) not previously treated with anti-G D2 mAb and in 4 of 47 (8.5%) previously exposed to 1 or 2 anti-G D2 mAbs. Among the 49 patients who received cycle 2, HAHA-positivity developed in 8 (16%), including in 2 of 10 patients (20%) not previously treated with anti-G D2 mAb and 6 of 39 (15%) previously treated with 1 or 2 anti-G D2 mAbs. Late HAHA positivity emerged in 2 patients after cycles 9 and 12. No substantial change in C3 complement or CH50 serum levels was observed after the infusion of hu3F8 on day 1 in cycle 1.
Tumor Responses
Antineuroblastoma activity (response, progression-free survival) at each dose level is included in eTable 1 in Supplement 2, and Table 2 summarizes results stratified by disease status and prior mAb treatment for the 31 patients with evaluable disease (Figure 1 ). Of the 31 patients, 14 (45%) had complete remission or partial response, 5 (16%) had stable disease (>5 months), 11 (35%) had early progressive disease, and 1 (3%) experienced DLT (with first infusion of hu3F8). Eight patients (26%) remained progression free at a median (range) of >37 (>22 to >54) months from the start of treatment, including 6 who received a vaccine 18 for further consolidation of remission after completing this trial. Among 24 patients who enrolled with refractory disease (excluding the patient with DLT during the first infusion of hu3F8), only 3 of the 10 patients (30%) treated with 4.8 mg/kg/cycle or less (approximately 144 mg/m 2 /cycle, dose level ≤7) had major responses (1 complete remission and 2 partial response), whereas 11 of 14 patients (79%) had major responses (5 complete remission and 6 partial response) with 5.4 mg/kg/cycle or higher (approximately 162 mg/m 2 /cycle, dose level ≥8), with an odds ratio of 2.6 (P = .02).
Among the 26 patients who enrolled in the second or later complete remission and no neuroblastoma evaluable for response (Table 1) , 5 (19%) remained progression free at a median (range) of >50 (>26 to >63) months from the start of treatment, including 2 who were treated after protocol with the vaccine 18 and1who received a cycle of low-dose maintenance chemotherapy and vaccine 18 after exiting the study because of early HAHA positivity.
Discussion
Notable findings regarding hu3F8 in this phase 1 trial included acceptable toxic effects without the need for inpatient monitoring and allowing timely dose escalation; low immunogenicity despite both previous treatment with anti-G D2 mAbs and repeated hu3F8 challenge; and major responses and prolonged progression-free survival in heavily previously treated patients. Pharmacokinetic findings supported using 3 doses of hu3F8 per cycle administered every other day compared with 4 or 5 doses with other anti-G D2 mAbs. [1] [2] [3] 19 Treatment was outpatient because the adverse effects were readily manageable, even with a dose of hu3F8 that was 2.5 times higher than the standard dosage of 75 mg/m 2 /cycle or 100 mg/m 2 / cycle of dinutuximab or m3F8. The explanation for the feasibility of such high dosing might be associated with the decreased complement activation observed with hu3F8 in vitro given that CDC is deemed partly responsible for the predominant toxic effects of anti-G D2 mAbs (ie, pain on days of treatment). The pain problem suggests that excessive CDC is not desirable. This concept prompted a study of hu14.18K322A, a humanized version of dinutuximab specifically constructed to reduce CDC and pain. 19, 20 Given the possible trade-off between manageable toxic effects and the well-established antineuroblastoma activity of CDC, it is reassuring that hu3F8 has less but still substantial CDC compared with m3F8. and the 70% to 80% human antimouse antibody positivity with multiple cycles of m3F8. [3] [4] [5] The HAHA positivity findings in this phase 1 trial approximate the sensitization of 8% to 28% of patients (not previously treated with anti-G D2 mAb)after1to6cyclesof dinutuximab and cytokines. 6, 10, [23] [24] [25] Clearly, the use of humanized or chimeric mAbs lessens but does not completely abrogate a humoral response that could hinder immunotherapy.
14 As expected with phase 1 trials, the study patients all had a dismal prognosis given the extent of their chemoresistant disease and/or 1 or more prior episodes of progressive disease. These conditions with high-risk neuroblastoma are widely considered to be lethal. 26 Yet patients with refractory disease achieved durable major responses and patients in second or later complete remission achieved prolonged progression-free survival (eTable 1 in Supplement 2). These welcome findings were noted in patients with or without prior exposure to 1 or more anti-G D2 mAbs. The substantially better response rate noted with higher hu3F8 dosages (≥162 mg/m 2 /cycle) is particularly relevant given that dinutuximab and m3F8 were tolerated only at a dosage of 100 mg/m 2 /cycle. The results in this phase 1 clinical trial and in the ongoing successor phase 2 clinical trial appear to have contributed to the US Food and Drug Administration granting, in August 2018, Breakthrough Therapy designation to hu3F8 in combination with GM-CSF for patients with persistent refractory neuroblastoma limited to bone marrow with or without evidence of concurrent bone involvement.
Limitations
One limitation of this trial is the single referral center setting. The other limitation is the small number of patients at each dose level, which is a well-recognized drawback of a phase I trial. 
PROTOCOL SUMMARY AND/OR SCHEMA
This phase I trial will assess the toxicity of the humanized anti G D2 antibody hu3F8 when combined with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in patients with high risk neuroblastoma. Hu3F8 is given intravenously (IV) and GM-CSF subcutaneously (sc). A fixed dose of GM-CSF will be used. Dosages of hu3F8 will be escalated in small cohorts of patients if there is no DLT. To limit 3F8 side-effects (pain, urticaria), patients may receive opiates, and antihistamines. Pharmacokinetics of hu3F8 in patients will be recorded. Anti-tumor effect will be measured.
OBJECTIVES AND SCIENTIFIC AIMS
Primary Objective:
• To establish the maximum tolerated dosage of hu3F8 when combined with GM-CSF.
Secondary Objectives:
• To study the pharmacokinetics of hu3F8 when combined with GM-CSF.
• To assess activity of hu3F8 plus GM-CSF against NB.
• To quantitate pain during hu3F8 and GM-CSF treatment.
• To study markers of granulocyte-mediated cytotoxicity and NK-mediated cytotoxicity, anti-hu3F8 immunity, and anti-tumor immunity before and after treatment with hu3F8/GM-CSF.
• To quantitate the response of marrow NB by quantitative reverse transcription-PCR.
BACKGROUND AND RATIONALE

Disease background:
NB is the most common extracranial solid tumor of childhood; 50-60% of patients present with an unresectable primary tumor and metastases in bone marrow (BM). [1] [2] Intensive induction chemotherapy and aggressive surgery have improved remission rates in young patients; [3] [4] [5] results have been less impressive in adolescents and adults in whom NB is especially chemoresistant.
6-8
Realization of an effective strategy for eradicating minimal residual disease (MRD) has remained a formidable challenge. Post-surgical use of local radiotherapy helps control MRD in the primary site. 9 Myeloablative therapy (with stem-cell support) and treatment with the vitamin A derivative 13-cis-retinoic acid are commonly used to eradicate MRD in distant sites.
10
Attempts at treatment intensification have met with both acute and long term side effects, both of grave concern for young patients. There is a scarcity of promising new agents, and to date, few if any target/pathway-specific small molecules have shown major clinical benefit in patients with NB, although many promising leads continue to accumulate.
11 With a cure rate of <30% at toxicity limits among stage 4 patients diagnosed at >18 months of age, there is substantial room for improvement. 
3.2
Rationale for anti-GD2: Monoclonal antibody (MoAb) therapy is an accepted treatment modality for cancers, with five MoAbs having received FDA approval for solid tumors in adults, including colorectal and breast cancer, non small cell lung cancer, squamous cell carcinoma and melanoma. [13] [14] This modality, however, has remained inadequately exploited for the treatment of [26] [27] [28] [29] Based on encouraging clinical responses in phase I studies, ch14.18 was tested in large phase II studies as consolidation therapy for stage 4 NB (German NB90 and NB97 studies). For the 166 patients >12 months at diagnosis, even though EFS was similar in patients receiving ch14.18 when compared to patients on maintenance chemotherapy, OS was improved, and the rate of BM relapse reduced in patients treated with ch14.18. 30 In 2001, the COG initiated a randomized phase III trial to study the efficacy of the combination of ch14.18 with GMCSF and IL-2 in preventing NB relapse in patients in CR after ASCT (ClinicalTrials.gov NCT00026312). 31 An interim analysis showed a highly significant improvement in PFS and OS at 2 years.
32
Efficacy of combination of murine 3F8 with a single cytokine GM-CSF on marrow disease among patients with primary refractory NB: m3F8, a murine IgG3 MoAb specific for GD2, induces cell death, and mediates efficient ADCC and CMC against NB in vitro.
23 ADCC appears to play an important role also in vivo. Among 80 patients with very high risk NB, (namely, stage 4 patients diagnosed at >18 months of age with metastases at diagnosis to bone or marrow, with chemoresistant marrow disease despite dose-intensive induction plus an aggressive salvage regimen), 80% achieved BM remission usually after 1 to 2 cycles of 5-day antibody plus GM-CSF therapy.
33
This response rate was much higher than when m3F8 was used alone. Patient who received subcutaneous (sc) GM-CSF (ClinicalTrials.gov NCT00072358) had significantly longer PFS and OS than those who received intravenous (iv) GM-CSF (ClinicalTrials.gov NCT00002560). Post-GMCSF ANC and activated adhesion molecule (CD11b) expression in the granulocytes were significantly higher among the sc GMCSF group. 3435 Since CD11b is critical in ADCC of NB, these findings are particularly relevant for the role of complement activation and enhancement of ADCC by betaglucan. [36] [37] Furthermore, murine IgG MoAbs including m3F8 have preferential binding to the Fc R2A-R131 over the Fc R2A-H131 present on myeloid effectors. The association of FCGR2A MEMORIAL SLOAN-KETTERING CANCER CENTER IRB PROTOCOL IRB#: 12-230 A (12) polymorphism and patient outcome was consistent with an anti-tumor effect of myeloid-ADCC.
38
Efficacy of murine 3F8 plus single cytokine GM-CSF and 13-cis-retinoic acid for high risk patients in first remission (Table 1) 39 : Given the activity of m3F8 against chemoresistant marrow disease, the use of m3F8 was expanded to patients in their first remission. 169 children diagnosed with stage 4 NB were enrolled in consecutive anti-GD2 murine MoAb 3F8±GM-CSF±13-cis-retinoic acid (CRA) protocols after achieving first remission (CR/VGPR). Regimen A (n=43 high-risk [HR] patients) used 3F8 alone; Regimen B (n=41 HR) used 3F8+(intravenous)GM-CSF+CRA, following stem cell transplant (SCT); Regimen C (n=85) used 3F8+(subcutaneous)GM-CSF+CRA, 46/85 following SCT, and 28/85 requiring additional induction therapy and were deemed ultra-high-risk (UHR). Marrow minimal residual disease (MRD) was measured by quantitative RT-PCR. Survival probability was calculated by Kaplan-Meier method, and prognostic variables analyzed by multivariate Cox regression model. At 5 years from the start of immunotherapy, progression-free survival (PFS) improved from 44% for HR patients on Regimen A, to 56% on Regimen B, and 62% on Regimen C. Overall survival (OS) was 49%, 61%, and 81%, respectively. PFS and OS of UHR patients were 36% and 75%, respectively. Relapse was mostly at isolated site. Independent adverse prognostic factors included UHR (PFS) and Post-MRD [postcycle-2 MRD] (PFS and OS), whereas the prognostic factors for improved outcome were missing killer immunoglobulin-like receptor ligand (PFS and OS), human anti-mouse antibody response (OS), and Regimen C (OS). 39 *SCT=autologous stem cell transplantation; CRA = 13-cis-retinoic acid; GMCSF = granulocyte-macrophage colony stimulating factor; iv = intravenous; sc = subcutaneous; ** Ultra high-risk (UHR) patients received additional cyclophosphamide ± topotecan or irinotecan for refractory disease after standard induction therapy before 3F8 immunotherapy.
Prognostic Variables following m3F8+GM-CSF
39 : Variables with univariate p<0.1 were included in the multivariate model (Table 2) . Regimens A and B were combined into a single category, since there was no significant difference between their effectiveness in the multivariate models. Positive Post-MRD (a measure of lack of responsiveness to immunotherapy) was an independent adverse prognostic factor for PFS and OS, while UHR (a measure of refractoriness to induction) was independently prognostic for adverse PFS. In contrast, missing KIR ligand had a favorable influence on PFS and OS. For OS, having HAMA response, and the addition of sc GM-CSF in Regimen C versus no GM-CSF (Regimen A) or iv GM-CSF (Regimen B) had an independent positive impact. However, the definitive proof of efficacy contributed by Regimen C will require randomized comparisons. When survival after relapse was analyzed, time-to-relapse and Regimen C were independent predictors of OS in a multivariable model. 
Rationale for quantitating BM minimal residual disease (MRD) by quantitative realtime polymerase chain reaction (qRT-PCR):
Curative strategies for stage 4 NB must encompass control of both the primary mass and distant disease. Dose-intensive chemotherapy has had a favorable impact on resectability of primary tumors and surgical removal of all visible tumor, followed by local radiotherapy, reduces the risk of relapse in the primary site to <10%. Doseintensive chemotherapy eliminated histologically evident BM involvement in 90% of high-risk cases. These encouraging results have shifted the focus of curative strategies to the problem of MRDwhich is readily assessed in BM. Adjuvant treatments, such as immunotherapy with MoAbs, may make gradual and not quantum changes in MRD, which by definition is beyond the sensitivity of conventional histologic or radiologic techniques. The availability of more sensitive methods for quantitating occult tumor cells in sequential BM specimens can allow determination of the efficacy and optimal duration of adjuvant treatment. The absence of detectable tumor cells in BM can serve as a surrogate end point for the adjuvant treatment strategy, while quantitative data on BM disease will help detect relapse earlier and indicate a need for a change in treatment. We and others have reported a series of studies aimed at improving the utility of BM testing, focusing on immunological and molecular methods for identifying MRD.
23-24
The limit of detection for immunocytology is 1/10 5 to 1/10 6 cells; qRT-PCR has slightly superior sensitivity with a range of 1/10 5 to 1/10 7 cells. The results suggest that using a panel of sensitive markers, BM MRD is highly predictive of clinical outcome for 3F8+GMCSF immunotherapy in all disease stages, i.e., patients in first CR/VGPR, those with primary refractory disease and patients in second remission. 40 A MRD marker panel of 4 genes have been adopted for all future studies in NB: cyclin D1 (CCND1), ISL LIM homeobox 1 (ISL1), paired-like homeobox 2b (PHOX2B), and GD2 synthase (B4GALNT1). Among patients treated with 3F8/GM-CSF in their first CR/VGPR (Table 2) , early MRD response was the strongest independent prognostic factor of both PFS and OS. 
3.4
Rationale for hu3F8: These favorable clinical outcomes of m3F8 in children would not be possible if m3F8 could not be given as multiple treatment cycles over months to years. Early (before the 4 th cycle of m3F8) human anti-mouse antibodies (HAMA) can delay treatment, prevent further cycles, or more importantly compromise the anti-tumor effects of MoAb treatment. 41 Patients with
MEMORIAL SLOAN-KETTERING CANCER CENTER IRB PROTOCOL IRB#: 12-230 A (12)
CNS/LM disease benefit from repeated intrathecal 131 I-3F8 injections partly because HAMA cannot cross the blood-brain barrier. [42] [43] Reducing or removing mouse epitopes should reduce HAMA response, although even chimeric antibodies can induce HACA (human anti-chimeric antibody) unless the patient is immunocompromised. 44 An obvious strategy is to humanize 3F8.
Hu3F8 was made using standard recombinant methods, transduced into CHO-DG44 cells and selected for high IgG expression. It was purified by protein A affinity chromatography, anion exchange membrane, viral and bacterial filters. Hu3F8 has advantages over 14.G2a and its chimeric form ch14.18 in affinity and antigen crossreactivity: (1) 10-fold slower k off which translates into 10-fold higher affinity, (2) Since affinity for antigen is a key determinant of efficacy in MoAb therapy, 45 only m3F8 demonstrated direct cytotoxicity on tumor cells in vitro in the absence of white cells or serum complement, (3) a slow k off allows longer retention of MoAb on the tumor cell surfaces, translating into more efficient ADCC and CMC, and (4) since m3F8 crossreacts with GD1b, although at low levels (4%), it is applicable for another common ganglioside in NB. Early (before the 4th cycle of antibody) development of human anti-mouse antibodies (HAMA) or human anti-chimeric antibody (HACA) can delay treatment, prevent further cycles, or more importantly compromise the anti-tumor effects of MoAb treatment. Our phase I study of hu3F8 suggests that development of human anti-humanized antibody (HAHA) is much less common and fewer treatment delays. Both blood mononuclear cell (PBMC)-ADCC and neutrophil (PMN)-ADCC of hu3F8 were superior (10 to >100 fold based on EC50, table 3) to that of m3F8 in vitro, while CMC was slightly less intense. This superiority was consistently observed in ADCC assays, irrespective of whether donor white cells or NK92 cells transfected with human CD16 or CD32 were used as killers. Cross-reactivity with other gangliosides was similar to that of m3F8. Fc-CH2 domain mutated version (hu14.18K322A) currently in clinical trial. Given these considerations over-drive of CMC is probably not desirable. It is reassuring that hu3F8 had less but still substantial CMC compared to m3F8.
3.5
Current status of anti-GD2 immunotherapy for stage high risk NB: There are currently two anti-GD2 antibodies in clinical use. As discussed above, we have used m3F8 in phase I and II studies with demonstrated clinical efficacy. Although toxicities are tolerable, pain and allergic reactions are clinically significant in the short term and development of HAMA often precludes repeated administration. Beginning in 2001, the COG conducted a randomized phase III trial to study the efficacy of the combination of ch14.18 with GM-CSF and IL-2 in preventing NB relapse in patients in CR/VGPR after SCT (ClinicalTrials.gov NCT00026312). 32 This showed efficacy at early time point with improvement in PFS and OS at 2 years. Long-term followup is pending. The trial necessitates the administration of iv IL2, a cytokine that is associated with significant toxicity. Furthermore, chimeric antibodies are often associated with the development of a human anti-chimeric antibody response.
54 When m3F8 was combined with a single cytokine GM-CSF (Table 1 and 2), the toxicity profile was substantially less compared to ch14.18+IL1+GM-CSF. 39 In addition, the 2 year PFS and OS were 7-9% superior to ch14.18+IL2+GM-CSF. We therefore propose to study the third generation anti-GD2 MoAb hu3F8 combined with GM-CSF. By conducting this study with GM-CSF alone (along with a companion study with IL2 but without GM-CSF) we will be able to answer the pertinent question of which cytokine(s) gives more side effects and which enhances the efficacy of anti-GD2 therapy. This is highly relevant given the added costs and substantial toxicities of the current combined regimen of c14.18+IL2+GMCSF used by COG.
Phase I study of hu3F8 (IRB# 11-009):
The phase I single agent hu3F8 clinical trial at MSKCC is currently on going. To date, a total of 24 patients have been enrolled, three to each of the first 4 dose levels, six to the fifth, and three to the sixth and seventh. The highest dose level completed, and therefore determined to be safe is dose level 6 which is 2.4 mg/kg total or 0.8 mg/kg/dose in 3 doses per week dosing schedule. Currently the trial is enrolling at dose level 7, the hu3F8 dose is 3 mg/kg total given in 3 doses on Monday, Wednesday, Friday at 1 mg/kg/dose (~35 mg/m2/day). Patients have received from 2 to 24 (median = 8.7) doses. To date, the sole DLT -and sole treatment-related grade 4 toxicity -was a transient elevation in liver enzymes in two patients (at dose levels 5 and 7). The only grade 3 treatment-related toxicities (all transient) were urticaria (two patients), emesis (one patient), and elevated liver enzymes (three patients). Grade 1-2 treatmentrelated toxicities were pain (all patients), allergic reaction (flushing, pruritus, wheezing) (thirteen patients), cough (nine patients), fever (eight patients), fatigue (nine patients), nausea (six patients), urticaria (six patients), emesis (grade 1 only, four patients), diarrhea (seven patients) and peripheral sensory neuropathy (two patients). Four patients have developed human anti-human antibodies (HAHA), three of whom had previous m3F8 exposure. For the 16 other patients with previous m3F8 treatments, no HAHA has developed with repeated cycles (1-12 cycles total). Thirteen patients (three patients at dose level 1, two at dose level 2, three at level 3, one at dose level 4 and two at dose levels 5 and 6) were removed from the study due to progressive disease, after receiving between 2 and 24 doses of antibody. A preliminary analysis of pharmacokinetic data from the current phase I suggests that the half life of hu3F8 is approximately 4.5 days. The design of the current study takes advantage of this information to optimize the dosing schedule for hu3F8. Furthermore, this study will permit determination of hu3F8 PK when administered on the three times/week schedule.
3.6
Rationale for GM-CSF: GM-CSF can amplify 3F8 anti-NB activity in patients via effects on granulocytes and macrophages. 34 Other reasons for combining GM-CSF with hu3F8 include: (1) granulocyte production is only transiently suppressed by chemotherapy, and GM-CSF increases neutrophil and eosinophil production and is well tolerated compared to other cytokines such as interleukin-2, 32,55 and (2) GM-CSF can activate monocytes-macrophages to phagocytose NB cells,
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and enhances the proliferation, maturation, and function of antigen-presenting cells that promote host anti-tumor response. Myeloid activation markers on granulocytes (CD11a, CD63, CD87, CD11b and its activation epitope CBRM1/5) were increased following GMCSF therapy among patients with metastatic NB. For CBRM1/5, the increase was in both frequency and mean fluorescence intensity. CBRM1/5 activation was significantly higher after scGMCSF than after ivGMCSF. CBRM1/5 activation was strongly correlated with patient outcome in a multivariable model. 34 The favorable results of m3F8 + GM-CSF in high risk neuroblastoma (Table 1) should provide a strong rationale for combination of hu3F8 with GM-CSF.
3.7
Significance and implications: Various strategies have been applied to induce or augment immune-mediated attack against cancer. However, few clinical trials have successfully used MoAbtargeted immunotherapy against solid tumors in children or adults, especially with ADCC as the key underlying immune mechanism. Building on the favorable results of m3F8, hu3F8 has several potential advantages over m3F8 and ch14.18 which include: (1) low immunogenicity allowing repeat treatments over years, (2) greatly improved ADCC potency, (3) longer serum half-life reducing the necessity of daily injections, (4) substantial reduction of pain side effects, anaphylactic or anaphylactoid reactions as well as immune complex diseases.
This phase I trial exploits recent findings that promise to optimize the anti-NB activity of 3F8/GM-CSF. Furthermore, qRT-PCR analysis of MRD response in BM, which has proven informative in past studies, will be applied to monitor anti-NB activity of the immunotherapy, with an emphasis on early recognition of treatment efficacy or responsiveness. Risk-related molecular guidelines can be rapidly incorporated into future treatment programs. With NB, where randomized trials are difficult to carry out because of the small number of affected patients, such quantitative analyses of future adjuvant strategies have great utility for rapidly identifying both the best agent and its optimal use in a curative treatment program.
OVERVIEW OF STUDY DESIGN/INTERVENTION
Design
This phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. Patients come off study if they have DLT during the first cycle, as defined in Section 9.2. Patients with no DLT and no progression of disease have the option of receiving an additional 3 cycles if human anti-hu3F8 (HAHA) is negative. Patients who complete 4 cycles of treatment without complications or disease progression have the option of continuing treatment for up to 24 months from their first dose of hu3F8. To limit 3F8 side-effects (pain, urticaria), patients may receive opiates, and antihistamines. Pharmacokinetics (Table 5 ) of hu3F8 in patients will be measured. Pain scores will also be recorded.
Intervention
Road Map/Schema: Once cycle consists of treatment with hu3F8 for 3 days (day 1, 3 and 5). GM-CSF is started 5 days in advance of each hu3F8 cycle at 250 mcg/m 2 /day (day -4 to day 0), and at 500 mcg/m 2 /day x 5 days (day 1 to day 5). Cycles are 5 days. Cycles are repeated at ~2-4 week intervals between first days of hu3F8, through 4 cycles. Patients who complete 4 cycles of treatment without complications or disease progression have the option of continuing treatment for up to 24 months from their first dose of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Evaluations before, during and after treatment are summarized in MEMORIAL SLOAN-KETTERING CANCER CENTER IRB PROTOCOL IRB#: 12-230 A (12) table 4 and 5. In addition, to further study the side effect of pain, patients will be asked to assess their pain on the days of treatment with hu3F8 at 3 different time points: (a) prior to commencement of hu3F8, (b) at least once during the acute pain episode when rescue pain medication doses are usually required and (c) prior to discharge from the Pediatric Day Hospital.
THERAPEUTIC/DIAGNOSTIC AGENTS
HUMANIZED MONOCLONAL ANTIBODY hu3F8-IgG1 (IND-112594)
5.1.1 Source and Pharmacology: Hu3F8 is a humanized antibody of the IgG1 subclass. It is purified by affinity and ion exchange chromatographies and filtered to remove pathogens including viruses. The final product is tested to assure that it is free of nucleic acid, viruses, bacteria, fungi, mycoplasma and pyrogens.
Supplier:
Hu3F8 is manufactured under GMP conditions by a contracted manufacturer as an investigational agent for MSKCC. Final sterile product vials of hu3F8 are prepared under GMP conditions by the MSKCC Clinical Grade Production Facility.
Formulation and Stability:
The purified antibody hu3F8 is frozen at -20 o C in glass vials, at 2 mg/ml in a 25 mM sodium citrate/sodium chloride buffer at pH 7.6. At -20 o C, hu3F8 is stable for at least 22 months. For IV use, hu3F8 should be thawed at ambient temperature and diluted in 5% human serum albumin. Each dose is Millipore (0.22 m) filtered before use.
Route of Administration: IV infusion.
5.2
Sargramostim (YEAST-DERIVED HUMAN RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR; GM-CSF) 5.2.1 Source and Pharmacology: Yeast derived recombinant human GM-CSF.
Supplier: LEUKINE (sargramostim) is distributed by Genzyme Corporation,
Cambridge, MA and manufactured by Bayer HealthCare Pharmaceuticals, Seattle, WA.
Formulation and Stability:
Sargramostim is available as a sterile, white, preservative-free, 250 mcg single use vial of lyophilized powder or a 500 mcg/1 mL injectable solution.
The 250 mcg vials require aseptic reconstitution with 0.5 mL Sterile Water for Injection, USP (without preservative). During reconstitution, the Sterile Water for Injection, USP should be directed at the side of the vial and the contents gently swirled to avoid foaming during dissolution. Avoid excessive or vigorous agitation; do not shake. The reconstituted sargramostim solutions are clear, colorless, isotonic with a pH of 7.4 ± 0.3, and contain 500 mcg/mL of sargramostim. The single-use 250 mcg vials contain no antibacterial preservative, and therefore should be administered as soon as possible, and within 6 hours following reconstitution. They are intended for single use only and should not be re-entered or reused. Do not save any unused portion for later administration. Do not use beyond the expiration date printed on the vial.
Vials containing 500 mcg/1 mL of sargramostim are already in solution and are multiple dose vials. For subcutaneous administration, further dilution is not required. Liquid sargramostim may be stored for up to 20 days at 2-8°C once the vial has been entered. Discard any remaining solution after 20 days.
Store sargramostim powder, or reconstituted solutions, under refrigeration at 2-8°C (36-46°F);
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do not freeze or shake.
Aseptic technique should he employed in the preparation of all sargramostim solutions. To assure correct concentration following reconstitution, care should be exercised to eliminate any air bubbles from the needle hub of the syringe used to prepare the diluent. Parenteral products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. 
Route of
RECRUITMENT PLAN
In <1 year, 18 NB patients were enrolled on the humanized-3F8 trial (11-009). We anticipate at least maintaining this accrual rate, which will allow rapid realization of preliminary conclusions, with completion of the trial in 2 years. Given the favorable prior efficacy-toxicity profile with m3F8/GM-CSF, we expect that all patients will complete the trial. Patients will be offered participation in this study by their attending physician in the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center. No patient will be identified for recruitment by chart review or direct advertising. The attending physician will be responsible for explaining the study, obtaining written informed consent, and registering the patient on study. Patients will mainly be children and adolescents because of the nature of NB (90% of patients are <6 years old at diagnosis). Patients of both sexes and all ethnic backgrounds are eligible for this study.
Some potential research participants/ research participant's legally authorized representatives (LAR) will discuss participation in this trial with a consenting professional while on site but for various valid reasons will leave without signing consents. As some of these patients might have far apart scheduled visits but would like to participate, consents, along with a cover letter (Appendix C), may be delivered by mail or facsimile to/from the potential research participant /LAR for review and signature.
Upon receipt of the consent documents, the consenting professional will conduct the consent discussion by telephone when the research participant or the LAR can read the document as it is discussed. All other applicable conditions for documentation of the informed consent will be met and the 1 signed copy will be returned to the consenting professional for signature and date.
As this consent process includes participants mailing back a signed consent document, the participant will be requested to mail the signed consent document as soon as possible. Patients will MEMORIAL SLOAN-KETTERING CANCER CENTER IRB PROTOCOL IRB#: 12-230 A (12) be provided with an overnight shipping label and envelope in which to return the consents to MSKCC. Once received, the consenting professional will sign and date the copy of the consent form and a completely signed copy will be mailed back to the participant for his/her records.
PRETREATMENT EVALUATION
Pretreatment evaluations should be completed within 30 days of start of treatment. Extent of disease evaluations, electrocardiogram and echocardiogram can be completed within 45 days prior to treatment provided that the patient has not received any treatment after the tests were completed.
8.1
Complete history and physical examination.
8.2
Complete blood count, serum creatinine, blood urea nitrogen, serum aspartate aminotransferase, serum alanine aminotransferase, serum lactate dehydrogenase, serum alkaline phosphatase, serum total bilirubin, albumin, sodium, potassium, chloride and bicarbonate.
Echocardiogram
Electrocardiogram
Urinalysis
8.6
Serum for analysis of human anti-hu3F8 antibody (HAHA) if applicable (i.e., for patients previously treated with m3F8, hu3F8, ch14.18, or hu14.18), anti-idiotypic antibody, and anti-anti-idiotypic antibody. Sera will be archived for baseline cytokine studies if needed. If the patient was previously treated with an antibody, any HAHA results since last antibody treatment can be used.
8.7
Genomic DNA from heparinized blood to test for KIR, FcRIIa, FcRIIIa, CR3 and C1q gene polymorphisms. 46, 52, 56 Effector functions of monoclonal antibodies including hu3F8 depends on their Fc functions, i.e. binding to FcR in ADCC or binding to C1q in CDC. This affinity is determined by polymorphic alleles which determine antibody effectiveness and patient outcome.
8.8
BM aspirates and biopsies from bilateral iliac crests for standard histochemical studies, as well as for immunocytology and other molecular markers of disseminated NB.
8.9
Urine VMA and HVA (recommended, but not required)
8.10
Imaging by computed tomography (CT) or magnetic resonance imaging (MRI) of primary tumor site, and/or metaiodobenzylguanidine (MIBG) scan 64 or positron emission tomography (PET) 65 .
Pregnancy test, if applicable
TREATMENT/INTERVENTION PLAN
9.1
General Outline: Hu3F8 is infused IV over ~30 minutes (Table 5 : Road Map) while GM-CSF is administered sc. To modulate pain from hu3F8, patients may be premedicated with analgesics (e.g. opiates such as hydromorphone) and antihistamines (e.g. diphenhydramine, hydroxyzine, or loratadine). Patients with no DLT and no progression of disease have the option of receiving a total of 4 cycles (~2-4 week intervals between first doses of hu3F8 in each cycle).
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Patients are considered on study through 24 months from start of hu3F8 until they start a different treatment or are removed as per Section 13.0. Hu3F8 is given 3 times (MWF) in the first week for each 5 day cycle. Hu3F8 dosage is escalated between patients (see section 9.4). At least 3 patients will be studied at each dosage level and dose escalations will only be carried out if 0/3 or ≤ 1/6 patients have DLT. At least six patients will be studied at the maximum tolerated dosage (MTD). No more than two patients will receive their first dose of hu3F8 within a 24 hour period. If HAHA develops, cycles with hu3F8 are deferred until HAHA titer decreases to below the upper limit of normal. Patients may receive local radiation therapy if medically indicated after cycle 1.
Patients who complete 4 cycles of treatment without complications or disease progression have the option of continuing treatment for up to 24 months from their first dose of hu3F8. Breaks between these cycles can be up to ~2 months.
Starting after cycle 2, all patients are allowed to increase their dosage level to the highest dosage level that just completed DLT assessment.
DLT
DLTs will include the following: • DLT of hypertension is defined as a need for antihypertensive medication for >24 hours. Patients are monitored by pulse oximeter and have blood pressure taken no later than 30 minutes after the end of IV infusion of hu3F8.
• Febrile neutropenia (ANC <500mm3) • Grade 3 or greater capillary leakage syndrome
The following grade 3 toxicities will not be considered a DLT if they resolve within 24 hours:
• Allergic reactions controlled with supportive care measures
The following grade 3 toxicities will not be considered a DLT if they resolve within 48 hours:
The following grade 3 or 4 toxicities will not be considered a DLT (and therefore patient is still eligible to receive additional cycles) if they return to equal to or less than grade 2 within 14 days. If toxicity occurs after dose 1 or dose 2 of hu3F8 the next doses should only be given if the toxicity improves to equal to or less than grade 2:
• Hepatic toxicity (elevated levels of transaminases and/or bilirubin)
In all other cases, DLT is defined as grade 3 or greater toxicities occurring through 21 days from the 1 st dose of Hu3F8 in cycle 1 with the exception of toxicities clearly related to disease activity or co-interventions. Of note, patients are routinely transfused for hemoglobin <8.0g/dL, which is the definition of grade 3 anemia; therefore this is not an evaluable toxicity.
9.3
Schedule: Hu3F8 is given iv. To modulate pain from 3F8, patients are premedicated with analgesics (e.g., hydromorphone) and antihistamines (e.g., diphenhydramine or hydroxyzine). Hu3F8 is started ~1 hr after GM-CSF. GM-CSF is dosed at 250 mcg/m 2 /day from day -4 to day 0 (e.g. Wednesday to Sunday), and is 500 mcg/m 2 /day on days +1 to 5 (e.g. Monday to Friday), as in the predecessor protocol (IRB #03-077). Patients come off study if progressive disease occurs or if there is DLT from hu3F8.
The break from end of a cycle to start of next cycle is ~2-to-4 weeks through 4 cycles. Breaks between subsequent cycles can be up to ~2 months. Patients who develop HAHA will have their treatments with hu3F8/GM-CSF delayed until their HAHA turns negative.
Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
Day 1:
hu3F8 infused iv over ~30 minutes.
Day 3: hu3F8 infused iv over ~30 minutes.
Day 5: hu3F8 infused iv over ~30 minutes.
Note: GM-CSF is not administered if ANC>20,000/ul by last documented CBC.
The treatment schedule may require minor adjustment as clinically indicated or due to circumstance (e.g., due to PDH closure for holidays or due to inclement weather). Patients can complete the missed day of hu3F8 the following week, so they receive 3 doses of hu3F8. GM-CSF will be continued through the hu3F8 make-up day at the 500 mcg/m2 dose.
9.4
Dose Escalation: Hu3F8 is dosed by mg per kg rather than by mg per m2. Unlike chemotherapy for which clearance ultimately depends upon cardiac output which is dependent upon BSA, antibody distribution and clearance depend on total blood volume which is determined not by BSA, but by weight. On the other hand, GM-CSF was dosed by m 2 , as was done by clinical trials published so far. In the phase 1 single-agent hu3F8 trial, a dose of 0.9 mg/kg was safe with only one reversible LFT DLT in 1 of 6 patients. The starting dose of hu3F8 in this hu3F8+GMCSF study is chosen as 0.3 mg/kg/dose, 3x/week (total dose 0.9 mg/kg/cycle). If none of the initial 3 patients at a given dosage level experience DLT, the next dosage level is studied in another cohort of 3 patients. If there is one DLT in the first three patients at any dosage level, a total of six patients will be treated at MEMORIAL SLOAN-KETTERING CANCER CENTER IRB PROTOCOL IRB#: 12-230 A (12) that dosage to be sure that ≤1 of 6 patients has DLT. Escalation will continue if one of the 6 patients experiences DLT. If >2 patients have DLT at any dosage, accrual to that dosage will be stopped; if 6 patients were accrued to the immediately preceding dosage, this will be deemed the MTD and the trial will be stopped; if only 3 patients were treated at the preceding dosage, the cohort will be expanded to six.
If life-threatening toxicity occurs in any patient, further accrual at that dosage will be stopped pending review by the Principal Investigator. Toxicity at each dosage level is evaluated during the 21 days following the first dose of hu3F8.
Dosage escalation of hu3F8 proceeds as follows: 10.1 CBC before GM-CSF on days 1-5 (results not necessary before administering GM-CSF) during cycle 1. During subsequent cycles, CBC before GM-CSF on days when hu3F8 is given (e.g., days 1, 3 and 5) and then approximately every 3 months for 24 months while on study. If ANC>20,000/uL, CBC will be repeated the next day. CBC will not be repeated after Day 5.
10.2
History and physical exam within approximately 3 days after iv hu3F8 during cycle 1. During subsequent cycles, history and physical exam are required before doses two and three and as clinically indicated, and then approximately every 3 months for 24 months while on study.
10.3
Patients are monitored by pulse oximeter and have blood pressure taken no later than 30 minutes after the end of iv infusion of hu3F8.
10.4 C3 and CH50 before and ~3 hours after 1 st dose of hu3F8 during cycle #1.
10.5
Urinalysis prior to each cycle and then approximately every 3 months for 24 months while on study.
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10.6 Serum will be obtained before each cycle of hu3F8 to assay for HAHA titers and at least approximately every 3 months for 24 months while on study.
10.7
Liver and kidney function blood tests (ALT, AST, alkaline phosphatase, albumin, bilirubin, BUN and creatinine) and serum electrolytes (sodium, potassium, chloride and bicarbonate) before dose two of hu3F8 and within approximately 3 days after dose three of hu3F8 for cycle 1. For subsequent cycles, these tests are required before doses one and two, and then at least approximately every 3 months while on study. LDH only prior to each cycle of hu3F8 and then approximately every 3 months while on study.
10.8
An electrocardiogram is performed after infusion of the third dose of hu3F8 during cycle 1. A second electrocardiogram is performed before the first dose of hu3F8 of cycle 2.
If clinically indicated, electrocardiograms should also be obtained before subsequent cycles.
10.9
Serum for Pharmacokinetic studies (Table 5) : Where feasible, this sample schedule will be followed for cycles 1 and if a patient chooses to dose escalate, during the first cycle of the escalated dose. When not feasible and for all other cycles, blood will be obtained preand ~5 minutes post-each hu3F8 infusion for serum trough and peak hu3F8 levels. Each PK sample is ~3-5 ml of blood; on Day 1 ~15-20 ml of blood will be taken for 4 PK samples; on subsequent days only one ~5 ml sample is taken. Under no circumstances will more than 5 ml/kg/day of blood be taken.
10
.10 Blood will be drawn for WBC phenotyping within a week before starting GM-CSF, and before GM-CSF injection on day 1 and on day 5 during cycle 1.
10.11
Blood will be drawn for cytokine profile analysis before 1 st dose of hu3F8 infusion and ~24 hours after the last dose of hu3F8 during cycle 1.
10.12
Blood to test for anti-tumor antibodies will be drawn before cycles 1 and 4 and then approximately every 3 months for 24 months. This is not planned to be an additional blood draw, as assay can be performed using a sample drawn for PK sample #1 or HAHA testing.
10.13
The following evaluations will be performed: (a) before cycle 3, (b) after cycle 4, and (c) then approximately every 3 months for 24 months while on study: 10.13.1 BM aspirates and biopsies from bilateral iliac crests for standard histochemical studies, as well as for immunocytology and other molecular markers of disseminated NB in patients with evidence of bone marrow involvement in the past one year; otherwise these studies are performed approximately every 3 months or at the discretion of the PI 
10.13.4
Imaging by computed tomography (CT) and/or magnetic resonance imaging (MRI) of primary or suspected tumor sites. These imaging modalities do not need to be repeated at each of the time points mentioned above, but instead will be repeated at the discretion of the PI.
10.14 Pain Assessment: Pain scores will be assessed using the Face, Legs, Arms, Cry, Consolability (FLACC) scale [57] [58] [59] and/or the Wong-Baker FACES or numeric pain scale 60 , as appropriate (see Appendix A for pain scales). Pain scores will be evaluated at the following time points: (a) prior to commencement of hu3F8, (b) at least once during the acute pain episode when rescue pain medication doses are required (based on m3F8 this is towards the MEMORIAL SLOAN-KETTERING CANCER CENTER end of the 30 minute infusion or soon after completion of antibody infusion) and (c) prior to discharge from the Pediatric Day Hospital. Pain scores will be assessed for all hu3F8 cycles. All research blood (as identified in the table) will be completed where feasible. Patients who are 10 kilograms or less in weight will only have research bloods drawn at the discretion of the Principal Investigator. *Where feasible, if a patient chooses to dose escalate, the first cycle of the escalated dose will have a PK sample schedule as in cycle 1. For other treatment cycles blood will be obtained preand ~5minutes post-each dose of hu3F8 for trough and peak serum hu3F8 levels.
TOXICITIES/SIDE EFFECTS
11.1 Adverse events are any unfavorable or unintended sign (including an abnormal laboratory finding) symptom or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure (attribution of unrelated, unlikely, possible, probable or definite). All observed adverse events, regardless of treatment group or suspected causal relationship to study drug will be recorded for cycles 1 and 2. After cycle 2, only grade 2 unexpected adverse events which are considered possibly, probably, or definitely related to protocol and adverse events ≥ 3 will be recorded. Adverse events will be identified and graded using the Common Toxicity Criteria Version 4.0 developed by the National Cancer Institute (NCI) of the USA. Next it will be determined if the adverse event is related to the medical treatment (attribution). Serious Adverse Events (SAEs) are defined in Section 17.2.
11.2
Hu3F8 is expected to have the following side-effects: pain, paresthesia, hypertension, hypotension, tachycardia, urticaria, fever, nausea, emesis, and rarely, diarrhea, serum sickness, hyponatremia, somnolence and posterior reversible encephalopathy syndrome (PRES). Other potential side-effects that may occur are bronchospasm, anaphylaxis, peripheral neuropathy, impaired accommodation of the eye, poor reactivity of pupils to light and elevated transaminases.
GM-CSF:
Common side-effects include bone pain, flushing, local reaction at site of injection, leukopenia shortly after injection, and decrease in platelet count. Rare side-effects (predominantly in adults) include allergic reactions, weight gain, pleural or pericardial effusion, pericardial embolism, thrombosis, and difficulty breathing after first injection.
12.0 CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT 12.1 Response duration is calculated from first day of treatment with hu3F8. 12.4 Adequacy of trial: All patients who fulfill the eligibility requirements and receive a first cycle of hu3F8 will have an adequate trial and are considered evaluable for protocol.
12.2
CRITERIA FOR REMOVAL FROM STUDY
13.1 Patients come off study if there is progressive disease at any time. Best clinical judgment will be used to determine whether a patient must undergo tests between cycles to make sure disease is not progressing. However, if a patient develops recurrent disease that can be completely eliminated surgically or eliminated by other means, that patient may remain on study at the discretion of the Principal Investigator as long as the patient does not receive systemic therapy and the recurrence is promptly eliminated.
13.2
Patients come off study if they have a life-threatening toxicity clearly attributable to the hu3F8.
13.3
The investigators will make every reasonable effort to keep each patient in the study until all planned treatments and assessments have been performed. The investigators may discontinue study drug treatment for the following reasons:
• Adverse events, including unacceptable toxicity or exacerbation of underlying disease, associated with study drug administration and necessitating discontinuation of treatment. Patients who are removed from the study due to adverse events will be treated and followed according to established, acceptable medical practice. All pertinent information concerning the outcome of such treatment will be entered in the MSKCC institutional Clinical Research Database (CRBD). Patients will be followed until resolution or stabilization of the adverse event.
• Withdrawal of consent. The patient's desire to withdraw from the study may occur at any time. The investigator should carefully consider whether the patient's withdrawal of consent is due to an adverse event, and if so, record the adverse event as the reason for withdrawal.
• Withdrawal by the physician for clinical reasons not related to study drug treatment in the absence of an adverse event.
• Violation of the study protocol, including failure to return for required treatments or assessments. Patients who fail to return for treatments will be withdrawn from the study if more than one scheduled dose is missed.
BIOSTATISTICS
14.1
Primary endpoint
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The main objective of the study is to establish the maximum tolerated dosage (MTD) of hu3F8 when combined with sc GM-CSF. DLT is defined after 1 cycle as specified in section 9.2. Seventeen dosage levels of hu3F8 will be tested (section 9), with three to six patients at each dosage level. Although both children and adults are eligible for enrollment on this study, we do not anticipate any significant differences in toxicity between adults and children as we have treated over 780 children under age 12 and over 100 patients over age 12 (including >50 over age 18) over the past 20 years with murine 3F8 with no measurable differences in toxicity. If no DLT is observed, hu3F8 dosage is advanced. If one DLT is observed in the first three patients at any level, three additional patients will be tested at the same dosage level. If two or more patients at any dosage level have DLT, the immediately preceding dosage will be defined as the MTD; if only 3 patients were treated at the preceding dosage, the cohort will be expanded to 6 patients. In this 3 + 3 phase I design, a maximum of 102 patients will be treated on this study: if there are no DLTs, 54 patients will be treated, completing the last dose level with 6 patients. In the unlikely event that patient stops the drug due to HAHA before completing the first cycle this patient will be considered inevaluable and will be replaced. It is expected that the study will accrue 10-20 patients per year and will last 4-5 years. On the basis of this trial, further dosage escalation of hu3F8 may be warranted.
The possibility of escalating given certain true rates of DLT is shown below:
For each dose level:
True rate of DLT 5% 10% 20% 30% 40% 50% 60% Probability of escalating 0. 
Accrual Rate
We expect to accrue 10-20 patients per year. This trial is expected to be completed within 4-5 years.
14.3 Secondary Endpoints 14.3.1 Pharmacokinetics of iv hu3F8 in the presence of scGM-CSF: Pharmacokinetics will be measured by serial blood sampling following the first two iv doses of hu3F8 as listed in Table 3 . Serum hu3F8 will be measured pre-infusion and at time pre-(within an hour before hu3F8), 5 min, 3h, 6-8h, 24h, 48h, 72h, 96, 120h, 168h 216h and 264h after the first infusion of hu3F8 during cycle 1 and, whenever possible, peak hu3F8 level at pre-and ~5 minutes post-infusion will also be measured for each dose of hu3F8 in subsequent cycles. PK analysis will be carried out by noncompartmental analysis of the serum concentration-time data using the WinNonlin software program (Pharsight Corp., Mountain View, CA). We expect PK of hu3F8 to reach steady state (ss) after the second dose. The following variables are determined: area under the serum concentrationtime curve from 0 to 264 hours (AUC 0-168 ), the maximum serum concentration (C max ), the time to reach the maximum concentration (t max ), and the terminal half-life (t 1/2 ). The variables AUC 0-168/τ,ss and C max(ss) are dose normalized (τ = 264-hour dosing interval) in order to calculate clearance (CL ss ), volume of distribution (V ss ) at steady state, the accumulation index for AUC (R A,AUC ), C max (R A,Cmax ), apparent terminal half-life, and mean residence time. These parameters will guide us in the future in designing phase II studies. Where feasible we will also repeat PK studies in subsequent cycles, for the purpose of comparing AUC and half lives of hu3F8 after multiple cycles of administration. 14.3.2 To assess activity of hu3F8 + GM-CSF against NB: Another secondary objective is to assess the anti-tumor activity of hu3F8 against NB and other GD2-positive tumors. Anti-tumor activity will be measured by international neuroblastoma response criteria (INRC). 61 14.3.3 Quantification of pain: As patient's pain will be assessed with a numerical score of 1 to 10 over the course of the treatment, a curve of pain intensity over time can be generated for each patient. We have been collecting similar pain data for patients being treated with murine 3F8 (control group) and may be able use this to compare to pain data of patients receiving hu3F8. We will focus on the first cycle for both hu3F8 and m3F8. Patients receiving m3F8 are treated with concurrent protocols at 20 mg/m 2 /day. Differences will be tested for significance using both Mann-Whitney and repeated measures ANOVA tests as described previously 62 . We plan to average scores for these control patients as each treatment is daily over 5 days as opposed to thrice weekly for hu3F8.
14.3.4 To study biologic correlates: Biologic correlate studies include (1) host immunity and (2) host WBC cytolytic capacity. The parameters measured for each patient under "host immunity" include: the induction of HAHA, the induction of Ab3, the induction of Ab3', the induction of antibody response to tumor antigen and secondary cytokine profile. Under cytolytic capacity, the following measurements will be made: (1) cytolytic capacity of NK and PMN, (2) activation markers (CD11b) on PMN and lymphocyte subsets and (3) FcR genetic polymorphism, and (4) missing KIR ligand. Host immunity and cytolytic capacities will be tested for association with patient MRD response and survival using logistic or Cox proportional hazards regression. These comparisons should provide insights into biologic effects of hu3F8 plus GM-CSF, and parameters that may predict response and survival. 14.3.5 BM MRD response: will be measured using quantitative Reverse transcription-PCR (qRTPCR) and its relationship with dosage of hu3F8 explored.
RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES
Research Participant Registration
Confirm eligibility as defined in the section entitled Criteria for Patient/Subject Eligibility.
Obtain informed consent, by following procedures defined in section entitled Informed Consent Procedures.
During the registration process registering individuals will be required to complete a protocol specific Eligibility Checklist.
All participants must be registered through the Protocol Participant Registration (PPR) Office at Memorial Sloan-Kettering Cancer Center. PPR is available Monday through Friday from 8:30am -5:30pm at 646-735-8000. Registrations must be submitted via the PPR Electronic Registration System (http://ppr/). The completed signature page of the written consent/RA or verbal script/RA, a completed Eligibility Checklist and other relevant documents must be uploaded via the PPR Electronic Registration System.
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Randomization
Not applicable
DATA MANAGEMENT ISSUES
A Research Study Assistant (RSA) will be assigned to the study. The responsibilities of the RSA include project compliance, data collection, abstraction and entry, data reporting, regulatory monitoring, problem resolution and prioritization, and coordinate the activities of the protocol study team. The data collected for this study will be entered into a secure database. Source documentation will be available to support the computerized patient record.
Quality Assurance
Registration reports will be generated by the RSA to monitor patient accruals and completeness of regsitration data. Routine data quailty reports will be generated to assess missing data and inconsistencies. Accrual rates and extext and accuracy of evaluations and follow-up will be monitored periodically throughout the study period and potential problems will be brought to the attention of the study team for discussion and action.
Random-sample data quality and protocol compliance audits will be conducted by the study team on an ongoing basis.
Data and Safety Monitoring
The There are several different mechanisms by which clinical trials are monitored for data, safety and quality. There are institutional processes in place for quality assurance (e.g., protocol monitoring, compliance and data verification audits, therapeutic response, and staff education on clinical research QA) and departmental procedures for quality control, plus there are two institutional committees that are responsible for monitoring the activities of our clinical trials programs. During the protocol development and review process, each protocol will be assessed for its level of risk and degree of monitoring required. Every type of protocol (e.g., NIH sponsored, in-house sponsored, industrial sponsored, NCI cooperative group, etc.) will be addressed and the monitoring procedures will be established at the time of protocol activation.
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The investigator agrees to conduct this study in accordance with the International Conference on Harmonization (ICH) principles of Good Clinical Practice and with the Declaration of Helsinki (1989) . The investigator will conduct all aspects of this study in accordance with all national, state, and local laws of the applicable regulatory agencies.
• Most patients will be children, adolescents, and young adults because of the nature of these tumors. Patients of both sexes and all ethnic backgrounds are eligible for this study. Alternative treatments are available and will be discussed with patient or legal guardian.
• Consent Process: Participation in this trial is voluntary. All patients will be required to sign a statement of informed consent, which must conform to MSKCC IRB guidelines.
• Benefits: It is not known whether this treatment will improve the overall survival of the patient.
• Risks: The potential risks of this therapy as described in Section 11 of this protocol may outweigh the potential benefits in an individual patient. The potential risks are related to adverse effects which could be induced by the infusion of hu3F8.
• Costs: Patients are responsible for the costs of physician visits, routine laboratory and radiographic studies, bone marrow aspirates and biopsies, hospitalizations, drug administration, outpatient care, and GM-CSF. Patients will not be charged for Hu3F8 or for research blood tests. If there is an injury as a result of this research study, emergency care, hospitalization, and outpatient care will be made available by Memorial Hospital and billed to the patient as part of the medical expenses. No money will be provided by Memorial Hospital as compensation for research-related injury. Patients will not be paid for taking part in this study.
• Confidentiality: Every effort will be made to maintain patient confidentiality.
Research and hospital records are confidential.
Privacy
MSKCC's Privacy Office may allow the use and disclosure of protected health information pursuant to a completed and signed Research Authorization form. The use and disclosure of protected health information will be limited to the individuals described in the Research Authorization form. A Research Authorization form must be completed by the Principal Investigator and approved by the IRB and Privacy Board (IRB/PB).
Serious Adverse Event (SAE) Reporting
Any SAE must be reported to the IRB/PB as soon as possible but no later than 5 calendar days. The IRB/PB requires a Clinical Research Database (CRDB) SAE report be submitted electronically to the SAE Office at sae@mskcc.org. The report should contain the following information:
Fields populated from CRDB: The PI's signature and the date it was signed are required on the completed report.
For IND/IDE protocols:
The CRDB AE report should be completed as above and the FDA assigned IND/IDE number written at the top of the report. If appropriate, the report will be forwarded to the FDA by the SAE staff through the IND Office.
Definition of SAE
Serious Adverse Events (SAEs) are any adverse events occurring at any dose while on treatment and within 30 days of the last dose of Hu3F8 that result in any of the following outcomes:
UNEXPECTED EVENT: Grades 2 -3: Attribution of Possible, Probable or Definite Grades 4 and 5: Regardless of Attribution. This includes all deaths within 30 days of the last dose of treatment with an investigational agent regardless of attribution.
Any late death attributed to the agent (possible, probable, or definite) should be reported within 5 calendar days.
EXPECTED EVENT Grades 1 -3: Adverse Event Expedited Reporting NOT required. Expected Grade 3 events with an associated hospitalization will be reported.
Grades 4 and 5: Regardless of Attribution. This includes all deaths within 30 days of the last dose of treatment with an investigational agent regardless of attribution.
Any event that is considered a DLT as defined in Section 9.2 will also be reported as an SAE.
For Hospitalization only -Any medical event equivalent to CTCAE (Version 4.0) Grade 3, 4, or 5 that precipitates hospitalization (or prolongation of existing hospitalization) must be MEMORIAL SLOAN-KETTERING CANCER CENTER IRB PROTOCOL IRB#: 12-230 A (12) receive a copy of the signed informed consent form. 
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